Pfizer CEO expects to submit children's COVID-19 vaccine data to FDA in days
Pfizer CEO Albert Bourla said Sunday that the company is planning to submit the data it compiled from COVID-19 vaccine trials for children between the ages of 5 and 11 to the Food and Drug Administration quite soon.
"It's a question of days, not weeks," he told ABC News' George Stephanopoulos on Sunday's edition of This Week.
Last week, Pfizer revealed that the vaccine it developed in tandem with BioNTech was safe and effective within the age group even with a smaller dose than the one that's been approved for ages 12 and up.
Article continues belowThe Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Once the FDA can review that information, the vaccine will be on track to become available for younger children, which will likely go a long way toward solidifying pandemic-related education policies throughout the U.S.
